Home Journals Books For Authors and Reviewers Online Submission News About Us Contact Us
Search
magazinelogo

International Journal of Clinical and Experimental Medicine Research

ISSN Print: 2575-7989 Downloads: 219189 Total View: 2502886
Frequency: quarterly ISSN Online: 2575-7970 CODEN: IJCEMH
Email: ijcemr@hillpublisher.com
Search articles within this journal Submit an article

Journal Menu

Volumes & Issues

Current Issue

Download PDF

How to cite this paper

7255

TOTAL VIEWS

More Articles

Article Open Access http://dx.doi.org/10.26855/ijcemr.2020.10.001

Immunohistochemical Expression of p53 Biomarker in Urinary Bladder Urothelial Carcinoma among Sudanese Patients

Roa ELsiddeg Mahjoub Hammed 1, Elsadig Ahmed Adam 2, Khalid Mohamed Khalid Elhussain 3,4,5,*

1 Department of Histopathology and Cytology, ALmadain College for Medical Science and Technology, Sudan.

2 Faculty of Medicine, Department of Pathology, The National Ribat University, Sudan.

3 Department of Hematology and Immunohematology, Omdurman Islamic University, Sudan.

4 Faulty of Medicine, Omdurman Ahlia University, Sudan.

5 Faculty of Medical Laboratory Sciences, International University of Africa, Sudan.

*Corresponding author: Khalid Mohamed Khalid Elhussain

Published: August 3,2020

Abstract

Background: Urothelial (transitional cell) bladder carcinoma UBC is the most common malignancy of the urinary tract and the seventh leading cancer in men worldwide. Mutations in P53 gene are the most common genetic abnormality inhuman cancer. Mutation of P53 gene results P53protein accumulation in cells’ nuclei. This accumulation is detectable with Immunohistochemical methods and correlates with P53 gene mutation. Aims: The study aimed to detect the expression of p53 in Urothelium cell carcinoma of urinary bladder using Immunohistochemical method, and correlate the expression of p53 with the gender, age of patient and histological grade. Methods: Forty paraffin embedded blocks previously diagnosed as transitional cell carcinoma were collected. This retrospective analytical study conducted at, Elalim Medical Laboratory Center and histopathology and cytology lab of ElRibat University Hospital, Soba University Hospital during the period from September 2015 to December 2016. Result: Immunohistochemical expression of p53 was revealed positive result of expression of p53 in 7 (17.5%) of high grade sample, and negative in 15 (37.5%) of them. While 4 (10%) of low grade sample show positive expression of p53 14 (35%) of sample show negative expression. 27 (67.5%) of patients were males, 5 (12.5%) of them were positive for p53 expression and 22 (55%) of them represent negative of p53 expression and 13 (32.5%) patients were female 6 (15%) of them were positive for p53. Patient from 15 to 35 years were 2 (5%) patients, 2 (5%) were negative expression of p53, from 36 to 55 years were 11 (27.5%) patients, 5 (12.5%) were positive expression of p53 and 6 (15%) negative from 56 to 75 years were 23 (57.5%) patient, 5 (12.5%) were positive expression of p53, 18 (45%) negative from 76 to 95 years were 4 (10%) patients, 1 (2.5%) were positive expression of p53, 3 (7.5%) were negative expression of p53. Conclusion: the correlation between the p53 expression and histological grades of the tumor show in-significant statistical association (p value=0.449). The correlation between the expression of the p53 with gender showed insignificant statically association (p value=0.067).The correlation between the expression of the p53 with age showed insignificant statically asso-ciation (p value=0.402).

References

[1] “Bladder Cancer Treatment (PDQ®)–Patient Version—National Cancer Institute”. (2020). www.cancer.gov. 11 May 2020. Retrieved 4 June 2020.

[2] Siegel, R. L., Miller, K. D., Jemal, A. (2020). Cancer statistics, 2020. CA A Cancer J. Clin. 2020, 70, 7-30. [CrossRef].

[3] Antoni, S., Ferlay, J., Soerjomataram, I., Znaor, A., Jemal, A., Bray, F. (2017). Bladder cancer incidence and mortality: A global overview and recent trends. Eur. Urol. 2017, 71, 96-108. [CrossRef] [PubMed].

[4] Kaseb H, Aeddula N R. (2020). CANCER, Bladder. 2020 Apr 24.

[5] Witjes J. A., Lebret T.,Compérat E.M., Cowann C., Desantis M., Bruinsh M., Hernández V., Espinós E. L., Dunn J., Rouanne M., et al. (2017). Updated 2016 EAU guideline on guscle-invasive and metastatic bladder cancer. Eur. Urol. 2017, 71: 462.

[6] J. Alfred Witjes, Thierry Lebret, Eva M. Compérat, Nigel C. Cowan, Maria De Santis, Harman Maxim Bru. (2016). 475. doi:10.1016/J.eururo.2016.06.020[PubMed][crossRef][Google Scholar]

[7] Babjuk., M., Böhle A., Burger M., Capoun O., Cohen D., Compérat E. M., Hernández V., Kaasinen E., Paloa J., Rouprét M., Eral. (2017). EAU guideline on non-muscle—invasive urothelial carcinoma of bladder: Updata 2016. Eur. Uro. 2017, 71: 447.

[8] 461. doi:10.1016/j.eururo.2016.05.041[PubMed][crossRef][Google Scholar].

[9] Babjuk M. (2017). Trends in bladder cancer incidence and mortality: success or disappointment? Eur. 2017, 71: 109-110. doi:10.1016/j.eururo.2016.06.040.

[10] Chen L., Liu Y., Li Q., Xie T., Wu Q., Sui X. (2019). P53/PCDH17/Beclin-1protein as prognostic predicators for urinary bladder cancer. J. Cancer. 2019, 10: 6207-6216. doi:10.7150/jac.37335[PMC Free article] [PubMed][crossRef][Google Scholar].

[11] Mitra, A. P. (2016). Molecular substratification of bladder cancer: Moving towards individualized patient management. Ther. Adv. Urol. 2016, 8, 215-233. [CrossRef].

[12] Correlation of P53 status with histological grading of urinary Bladder Transitional cell carcinoma, Mamata Medical College, Khamma.

[13] Ibrahim N., Elzagheid A., El-Hashmi H., Syrjänen K., and Alhakim S. (2009). The Potential Value of EGFR and P53 Immu-nostaining in Tumors of the Urinary Bladder. Libyan Journal of Medicine 2009, 4(4): 143-145.

[14] Vijay Kumar P, Sushma Yalavarthi, Rukmangadha L. (2017). Correlation of p53 status with histological grading of urinary Bladder Transational cell Carcinoma. doi10.21276/Sjams.2017.5.1.55.

[15] Immunoreactivity of p53 in Urothelial Carcinoma of the Urinary bladder. doi:10.7860/NJLM/2018/39790:2324.

[16] Milena Matuszczak and Maciej Salagierski. (2020). Diagnostic Potential of Biomarkers CYFRA 21.1, ERCC1, P53, FGFR3 and TATI in bladder Cancer. Published online 2020 May 9 doi:10.3390/ijms21093360.

[17] Olaf Hammam, Mona Magdy, and Tark EleitHy. (2017). Expression of MDM2 Mrna, MDM2, P53 and P16 proteins in Uro-thelial Lesions in the View of the WHO 4th Edition Guidelines as a Molecular Insight towards Personalized Medicine. 19 May 2017.

[18] Koki, K. (2018). Immunohistochemical expression of HER 2 NEU, P53 & P63 in urothelial bladder carcinoma and its correlation with clinico-pathological variables. 

[19] Noor Al-huda Ali A. H.Saeed, Ban Talib El-Haboby, SamarAbdula Raheem Al-Gharrawi. (2015). Correlation Between Tumor Suppressor Gene P53 and Bladder Cancer in Some Iraqi Patients.

How to cite this paper

Immunohistochemical Expression of p53 Biomarker in Urinary Bladder Urothelial Carcinoma among Sudanese Patients

How to cite this paper: Roa ELsiddeg Mahjoub Hammed, Elsadig Ahmed Adam, Khalid Mohamed Khalid Elhussain. (2020) Immunohistochemical Expression of p53 Biomarker in Urinary Bladder Urothelial Carcinoma among Sudanese Patients. International Journal of Clinical and Experimental Medicine Research, 4(4), 112-116.

DOI: http://dx.doi.org/10.26855/ijcemr.2020.10.001

Home　|　Journals　|　Books　|　For Authors and Reviewers　|　Online Submission　|　Contact Us　|　About Us

Copyright © 2023 Hill Publishing Group Inc. All Rights Reserved.